Literature DB >> 12446549

Hormone replacement therapy. Logically, long term hormone replacement therapy cannot be recommended.

Kishore Shetty.   

Abstract

Mesh：

Year:  2002        PMID： 12446549      PMCID： PMC1124702     

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  7 in total

1.  Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.

Authors:  C Schairer; J Lubin; R Troisi; S Sturgeon; L Brinton; R Hoover
Journal:  JAMA       Date:  2000-01-26       Impact factor: 56.272

2.  Failure of estrogen plus progestin therapy for prevention.

Authors:  Suzanne W Fletcher; Graham A Colditz
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

Review 3.  Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease.

Authors:  Linda L Humphrey; Benjamin K S Chan; Harold C Sox
Journal:  Ann Intern Med       Date:  2002-08-20       Impact factor: 25.391

4.  Hormone replacement therapy.

Authors:  John C Stevenson; Malcolm I Whitehead
Journal:  BMJ       Date:  2002-07-20

5.  Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy.

Authors:  C Magnusson; J A Baron; N Correia; R Bergström; H O Adami; I Persson
Journal:  Int J Cancer       Date:  1999-05-05       Impact factor: 7.396

Review 6.  Treatment of postmenopausal osteoporosis.

Authors:  Pierre D Delmas
Journal:  Lancet       Date:  2002-06-08       Impact factor: 79.321

7.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.